Key Takeaways
- Jardiance (empagliflozin) produces an average weight loss of about 2 to 3 kg (roughly 4 to 7 pounds) over 24 to 52 weeks in patients with type 2 diabetes (Zinman et al., NEJM 2015).
- Jardiance is not FDA-approved for weight loss. It's approved for type 2 diabetes, heart failure, and chronic kidney disease.
- Weight loss from Jardiance happens because the kidneys excrete about 70 to 90 grams of glucose per day in urine, which equals roughly 280 to 360 calories lost daily (Ferrannini et al., Diabetes Care 2014).
- GLP-1 receptor agonists produce 5 to 10 times more weight loss than Jardiance over the same period (Frias et al., NEJM 2018).
- Jardiance can be combined with a GLP-1 in patients with type 2 diabetes when both blood-sugar control and weight reduction are goals.
Direct answer (40-60 words)
Jardiance (empagliflozin) causes modest weight loss of about 2 to 3 kg (4 to 7 pounds) over 6 to 12 months in patients with type 2 diabetes. The mechanism is glucose excretion through urine, which removes roughly 280 to 360 calories daily. It's not FDA-approved for weight loss and produces far less weight reduction than GLP-1 medications.
Table of contents
- The 30-second answer
- What Jardiance is and what it's actually approved for
- How much weight people lose on Jardiance: the clinical trial numbers
- Why Jardiance causes weight loss: the glucose-in-urine mechanism
- Why the weight loss plateaus
- Jardiance vs GLP-1 medications for weight loss
- Combining Jardiance with semaglutide or tirzepatide
- Who Jardiance is right for, and who it isn't
- Side effects that affect weight and water status
- FAQ
- Sources
- Footer disclaimers
What Jardiance is and what it's actually approved for
Jardiance is the brand name for empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor manufactured by Boehringer Ingelheim and Eli Lilly. The FDA has approved it for three indications: type 2 diabetes (2014), reducing cardiovascular death in adults with type 2 diabetes and heart disease (2016), and heart failure plus chronic kidney disease (added 2021 and 2023). Weight loss is not on the label.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →The medication blocks SGLT2 receptors in the kidneys. Normally these receptors reabsorb glucose back into the bloodstream after the kidneys filter it out. Block them, and glucose leaves the body in urine instead. About 70 to 90 grams of glucose per day exit through urine on a standard 10 mg or 25 mg dose, depending on baseline blood sugar.
Weight loss is a side effect of that mechanism. It's real, it's measurable, and it's small.
How much weight people lose on Jardiance: the clinical trial numbers
Across the major trials, average weight loss on Jardiance falls in a tight range.
| Trial | Population | Dose | Duration | Average weight change |
|---|---|---|---|---|
| EMPA-REG OUTCOME (Zinman et al., NEJM 2015) | T2D + cardiovascular disease, N=7,020 | 10/25 mg | 3.1 years | -2.0 kg vs placebo |
| EMPEROR-Reduced (Packer et al., NEJM 2020) | Heart failure, N=3,730 | 10 mg | 16 months | -1.8 kg vs placebo |
| EMPA-REG MONO (Roden et al., Lancet D&E 2013) | T2D drug-naive, N=899 | 10/25 mg | 24 weeks | -2.5 kg vs placebo |
| Pooled meta-analysis (Liakos et al., D&O Metabolism 2014) | T2D, N=4,480 | 10/25 mg | 24 weeks | -2.04 kg vs placebo |
In plain English: most patients lose 4 to 7 pounds over the first 6 to 12 months. Some lose 10 to 15 pounds. A small minority lose nothing, or gain weight if they increase calorie intake to compensate for the urinary glucose loss.
Compare that to a GLP-1: tirzepatide at 15 mg produced 21% mean body weight loss in SURMOUNT-1 (Jastreboff et al., NEJM 2022), or about 22 kg in a 100-kg patient. Jardiance produces roughly one tenth of that.
Why Jardiance causes weight loss: the glucose-in-urine mechanism
The math on Jardiance weight loss is simple, and the simplicity explains why the effect is small.
When the kidneys filter blood, they reclaim almost all the glucose through SGLT2 transporters in the proximal tubule. Block the transporters and 70 to 90 grams of glucose per day pass into urine instead, depending on plasma glucose levels (Ferrannini et al., Diabetes Care 2014). At 4 calories per gram of carbohydrate, that's 280 to 360 calories per day flushed away.
If nothing else changes, 280 calories a day deficit equals about 0.6 pounds of fat lost per week, or roughly 8 pounds in three months.
Real-world weight loss is smaller than that arithmetic predicts because:
- The body senses calorie loss and increases hunger. Most patients eat slightly more on Jardiance to compensate, partially offsetting the deficit.
- Glucose excretion is dose-saturable. After about 70 to 90 grams per day, the body can't lose more even at higher doses.
- A meaningful chunk of early weight loss is water. SGLT2 inhibition causes mild osmotic diuresis (urinary water loss), which shows up on the scale in week one and stabilizes by week four.
After the body adapts, the net deficit settles around 100 to 150 calories per day, which produces the 2 to 3 kg loss seen in trials.
Why the weight loss plateaus
The plateau happens for two reasons.
First, glucose excretion is capped. The kidneys can only dump so much glucose per day. Doubling the dose from 10 mg to 25 mg adds roughly 10 to 15 grams per day of additional glucose excretion, not double.
Second, appetite compensates. A 2014 paper by Ferrannini and colleagues in Journal of Clinical Investigation measured energy intake on empagliflozin and found patients ate about 13% more food, on average, by week 12 compared to baseline. The increase wasn't conscious. It was the body's homeostatic response to losing calories in urine.
This is why Jardiance plus a GLP-1 can produce more weight loss than either alone. The GLP-1 suppresses the appetite increase that would otherwise compensate for the urinary glucose loss.
Jardiance vs GLP-1 medications for weight loss
A direct comparison.
| Medication | Mechanism | Mean weight loss | Typical use case for weight loss |
|---|---|---|---|
| Jardiance (empagliflozin) | Renal glucose excretion | 2-3 kg over 6-12 months | T2D patients where modest weight loss is a bonus |
| Compounded semaglutide | GLP-1 receptor agonist | 12-15% body weight at 68 weeks | Primary weight-loss intervention |
| Compounded tirzepatide | GLP-1 + GIP receptor agonist | 18-22% body weight at 72 weeks | Strongest weight-loss option |
| Wegovy (semaglutide 2.4 mg) | GLP-1 receptor agonist | 14.9% body weight at 68 weeks | FDA-approved obesity medication |
| Zepbound (tirzepatide) | GLP-1 + GIP receptor agonist | 20.9% body weight at 72 weeks | FDA-approved obesity medication |
The 5x to 10x difference in weight loss reflects how each drug works. GLP-1 medications act on the brain's appetite centers and slow stomach emptying, producing a sustained calorie deficit of 500 to 1,000 calories per day. Jardiance produces a much smaller deficit through a single peripheral mechanism.
If weight loss is your only goal, Jardiance is not the right tool. If blood sugar control, kidney protection, or heart failure management is your goal and modest weight loss is a welcome bonus, Jardiance fits.
For more on how GLP-1 medications drive larger weight loss, see our GLP-1 mechanism explainer.
Combining Jardiance with semaglutide or tirzepatide
Pairing an SGLT2 inhibitor with a GLP-1 is a common diabetes strategy. The two classes work through completely different mechanisms, so their effects add up.
A 2018 study by Frias and colleagues in NEJM tested exenatide (a GLP-1) plus dapagliflozin (an SGLT2) versus either alone in type 2 diabetes patients. The combination produced 3.4 kg more weight loss than dapagliflozin alone and 1.5 kg more than exenatide alone over 52 weeks. The mechanisms didn't fight each other.
A 2020 paper by Ludvik and colleagues in Lancet (SURPASS-3) showed similar additive effects with tirzepatide plus SGLT2 background therapy.
In practice, combining the two classes makes sense when:
- A patient has type 2 diabetes plus heart failure or kidney disease (Jardiance covers those indications)
- A patient needs more glucose-lowering than a GLP-1 alone provides
- A patient's weight loss has plateaued on a GLP-1 alone
The combination requires careful monitoring for dehydration, ketoacidosis, and hypoglycemia (especially if either drug is used with insulin or a sulfonylurea).
Who Jardiance is right for, and who it isn't
Right for:
- Adults with type 2 diabetes, especially those with cardiovascular disease, heart failure, or chronic kidney disease
- Patients whose A1C needs lowering by 0.5 to 0.8 percentage points
- Patients who want a once-daily oral pill instead of an injection
- Patients for whom modest weight loss is a welcome side effect, not the main goal
Not the right tool for:
- Patients without diabetes whose primary goal is weight loss
- Patients with type 1 diabetes (off-label, increased ketoacidosis risk)
- Patients with severe kidney disease (eGFR below 20 mL/min for the diabetes indication)
- Patients with frequent urinary tract infections or genital yeast infections
- Patients with a history of diabetic ketoacidosis
For a patient whose only goal is weight loss and who doesn't have diabetes, a GLP-1 medication or a multidisciplinary obesity treatment plan will produce far better results than Jardiance.
Side effects that affect weight and water status
Jardiance's side effect profile relates directly to its mechanism.
Common (5 to 10% of patients):
- Genital yeast infections (about 5 to 10% of women, lower in men)
- Increased urination, especially in the first 4 weeks
- Urinary tract infections
- Mild dehydration, particularly in older adults
Less common but worth knowing:
- Diabetic ketoacidosis (rare in type 2, more concerning if used off-label in type 1)
- Volume depletion symptoms (dizziness, low blood pressure on standing)
- Genital infections, including the rare but serious Fournier's gangrene (FDA warning, 2018)
The water loss matters for weight tracking. Patients often see a 2 to 3 pound drop on the scale in the first week or two that's mostly water, not fat. By week four the water loss stabilizes, and any further weight loss reflects fat mass change.
A 2016 FDA black-box update noted that SGLT2 inhibitors can cause acute kidney injury in dehydrated patients. Drinking enough water is important, especially during hot weather or strenuous exercise.
How long until weight loss starts and plateaus
The typical Jardiance weight-loss timeline:
- Week 1-2: 2-3 pounds, mostly water from osmotic diuresis
- Week 4-8: Additional 2-4 pounds from fat loss
- Month 3-6: Slow ongoing loss to a total of 4-7 pounds
- Month 6-12: Plateau. Weight typically stabilizes at the new lower point
- Year 1+: Most patients maintain the loss without further reduction
If a patient hasn't lost weight by month 4, it's unlikely Jardiance alone will produce meaningful weight reduction. At that point, providers often add or switch to a GLP-1 if weight loss is a clinical priority.
FAQ
Does Jardiance cause weight loss? Yes, modestly. Most patients lose 4 to 7 pounds over 6 to 12 months. A small percentage lose 10 to 15 pounds. The mechanism is glucose excretion through urine, which produces a small daily calorie deficit. It's not approved for weight loss, but the effect is real.
How much weight can I lose on Jardiance? Average weight loss is 2 to 3 kg (4 to 7 pounds) at one year. Heavier patients sometimes lose more in absolute terms. Anything beyond 10 pounds is unusual on Jardiance alone and usually reflects diet and exercise changes happening alongside.
Is Jardiance approved for weight loss? No. Jardiance is FDA-approved for type 2 diabetes, heart failure, and chronic kidney disease. Using it solely for weight loss is off-label and not the recommended approach. GLP-1 medications produce far more weight loss and have weight-loss-specific FDA approvals.
How does Jardiance compare to Ozempic for weight loss? Ozempic (semaglutide) produces about 5 times more weight loss than Jardiance. Average semaglutide weight loss is 12 to 15% of body weight, compared to 2 to 3% for Jardiance. The two medications work through different mechanisms and can be combined in diabetic patients.
Can I take Jardiance and semaglutide together? Yes, in patients with type 2 diabetes. The combination is well-studied (Frias et al., NEJM 2018) and produces additive weight loss and glucose lowering. It requires monitoring for dehydration and is not used in non-diabetic patients seeking weight loss.
How fast does weight loss happen on Jardiance? Most weight loss occurs in the first 3 to 6 months. After that, weight typically plateaus. The first 1 to 2 weeks show 2 to 3 pounds of water loss, followed by gradual fat loss of about half a pound per week for two to three months.
Will I gain the weight back if I stop Jardiance? Often, yes. The urinary glucose excretion stops within 1 to 2 days of discontinuing Jardiance. If your eating habits haven't changed during the medication, weight typically returns to baseline within 3 to 6 months.
Does Jardiance work better at the 25 mg dose for weight loss? Marginally. Glucose excretion saturates above 10 mg, so the additional weight-loss benefit at 25 mg is small (about 0.5 kg more over 24 weeks). The 25 mg dose is more often chosen for stronger blood-sugar control rather than weight reduction.
Is Jardiance covered by insurance for weight loss? No. Insurance covers Jardiance for its approved indications (type 2 diabetes, heart failure, kidney disease). Off-label prescriptions for weight loss are typically denied. The cash price is roughly $600 to $700 per month without insurance.
Does Jardiance suppress appetite? Not directly. Unlike GLP-1 medications, Jardiance doesn't act on the brain's appetite centers. Some patients report mild appetite reduction, but it's a much weaker effect than what GLP-1 medications produce. Most patients feel slightly hungrier on Jardiance, which is why the weight loss plateaus.
Is Jardiance safer than a GLP-1 for weight loss? Different risk profiles, not directly comparable. Jardiance carries risks of genital infections, dehydration, and rare ketoacidosis. GLP-1s carry risks of nausea, vomiting, and rare pancreatitis. Both have established safety records when used appropriately. The choice depends on the patient's overall health picture.
Can people without diabetes take Jardiance for weight loss? Off-label, yes, but it's rarely worth it. Non-diabetic patients lose less weight on Jardiance than diabetic patients (because the glucose excretion is smaller in patients with normal blood sugar). Insurance won't cover it. The cash price is high. A GLP-1 makes more sense for non-diabetic weight loss.
Sources
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME). N Engl J Med. 2015;373:2117-2128.
- Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure (EMPEROR-Reduced). N Engl J Med. 2020;383:1413-1424.
- Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2013;1:208-219.
- Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:984-993.
- Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499-508.
- Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to SGLT2 inhibition. Diabetes Care. 2014;63:2812-2820.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
- Frias JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes (DURATION-8). Lancet Diabetes Endocrinol. 2016;4:1004-1016.
- Ludvik B, Giorgino F, Jodar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021;398:583-598.
- FDA Drug Safety Communication: FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. August 2018.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
- American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2026;49(Suppl 1).
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Jardiance is a registered trademark of Boehringer Ingelheim. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.